Held SAE - Search Results

1

Generation and functional characterization of MDSC-like cells.

Heine A, Held SAE, Schulte-Schrepping J, Wolff JFA, Klee K, Ulas T, Schmacke NA, Daecke SN, Riethausen K, Schultze JL, Brossart P. Heine A, et al. Among authors: held sae. Oncoimmunology. 2017 Feb 23;6(4):e1295203. doi: 10.1080/2162402X.2017.1295203. eCollection 2017. Oncoimmunology. 2017. PMID: 28507805 Free PMC article.

2

Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen.

Schmidt SM, König T, Bringmann A, Held S, von Schwarzenberg K, Heine A, Holderried TA, Stevanovic S, Grünebach F, Brossart P. Schmidt SM, et al. Leukemia. 2009 Oct;23(10):1818-24. doi: 10.1038/leu.2009.138. Epub 2009 Jul 16. Leukemia. 2009. PMID: 19609282

3

RNA vaccines in cancer treatment.

Bringmann A, Held SA, Heine A, Brossart P. Bringmann A, et al. J Biomed Biotechnol. 2010;2010:623687. doi: 10.1155/2010/623687. Epub 2010 Jun 1. J Biomed Biotechnol. 2010. PMID: 20625504 Free PMC article. Review.

4

Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone.

Kock G, Bringmann A, Held SA, Daecke S, Heine A, Brossart P. Kock G, et al. Blood. 2011 Mar 31;117(13):3569-74. doi: 10.1182/blood-2010-08-302224. Epub 2011 Feb 4. Blood. 2011. PMID: 21296999 Free article.

5

Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides.

Held SA, Duchardt KM, Tenzer S, Rückrich T, von Schwarzenberg K, Bringmann A, Kurts C, Schild H, Driessen C, Brossart P, Heine A. Held SA, et al. Cancer Immunol Immunother. 2013 Apr;62(4):715-26. doi: 10.1007/s00262-012-1373-7. Epub 2012 Nov 25. Cancer Immunol Immunother. 2013. PMID: 23184338 Free PMC article.

6

Regression of liver metastases after treatment with oxaliplatin/capecitabine and development of a progressive multifocal leukoencephalopathy in a patient with advanced thymoma.

Heine A, Schmiedel A, Menschik T, Held SA, Erdmann C, Brossart P. Heine A, et al. J Clin Oncol. 2013 Apr 20;31(12):e203-5. doi: 10.1200/JCO.2012.43.8150. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509314 No abstract available.

7

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P. Heine A, et al. Blood. 2013 Aug 15;122(7):1192-202. doi: 10.1182/blood-2013-03-484642. Epub 2013 Jun 14. Blood. 2013. PMID: 23770777 Free article.

8

Advances in immunotherapy of chronic myeloid leukemia CML.

Held SA, Heine A, Mayer KT, Kapelle M, Wolf DG, Brossart P. Held SA, et al. Curr Cancer Drug Targets. 2013 Sep;13(7):768-74. doi: 10.2174/15680096113139990086. Curr Cancer Drug Targets. 2013. PMID: 23906051 Review.

9

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.

Heine A, Held SA, Daecke SN, Riethausen K, Kotthoff P, Flores C, Kurts C, Brossart P. Heine A, et al. PLoS One. 2015 Jun 4;10(6):e0128897. doi: 10.1371/journal.pone.0128897. eCollection 2015. PLoS One. 2015. PMID: 26042424 Free PMC article.

10

Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.

Koerber RM, Held SAE, Heine A, Kotthoff P, Daecke SN, Bringmann A, Brossart P. Koerber RM, et al. Among authors: held sae. Exp Hematol Oncol. 2015 Aug 5;4:21. doi: 10.1186/s40164-015-0016-z. eCollection 2015. Exp Hematol Oncol. 2015. PMID: 26251761 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters